Latest Commercial Production News

Page 1 of 57
ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.
Victor Sage
Victor Sage
5 Oct 2026
Accelerate Resources has completed three large-diameter diamond holes at its Area 42 manganese project, with visual mineralisation recorded in each hole. The standout hole covered a 72m downhole span and ended in mineralised chert breccia, but assays and metallurgical results are still pending.
Maxwell Dee
Maxwell Dee
5 Oct 2026
Vertex Minerals’ Reward Gold Mine produced 679 ounces in its first production year, but the transition came with a A$16.4 million loss, negative operating cash flow and a formal going-concern warning. The company now faces a narrow window to prove its mechanised mining plan can lift production before debt repayments and further funding decisions bite.
Maxwell Dee
Maxwell Dee
2 Oct 2026
Aeris Environmental’s FY2026 annual report pairs international commercial progress with a $5.03 million operating cash drain, $9.22 million in net liabilities and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The company says it will need extended related-party loan terms and further funding while converting its technology and chemicals pipeline into recurring revenue.
Victor Sage
Victor Sage
1 Oct 2026
FirstWave Cloud Technology has sharply reduced its FY26 loss and generated positive operating cash flow as network monitoring and Latin American revenue accelerated. But a $5.35 million net current asset deficiency, covenant breach and planned capital raise leave the turnaround dependent on continued execution.
Victor Sage
Victor Sage
1 Oct 2026
Tolu Minerals has set out a Q1 2027 restart target for its Tolukuma gold-silver mine in Papua New Guinea, backed by a recently upgraded 909,000-ounce resource and refurbishment of an existing processing plant. The company says it has sufficient funding to reach production, but the timetable remains dependent on mine development, plant work and operating execution.
Maxwell Dee
Maxwell Dee
1 Oct 2026
Elixir Energy has begun the second phase of flow testing at Lorelle-3H after a 60-day reservoir soak, moving the Queensland appraisal well closer to a potential maiden Reserves booking. Success could position the well as a foundation producer for the proposed Warkon Pilot.
Maxwell Dee
Maxwell Dee
1 Oct 2026
Broken Hill Gold has recast itself from explorer to South Australian gold operator, producing its first doré while uncovering a deeper gold-copper sulphide system at White Dam. The transformation came with a $14.46 million FY2026 loss and continuing reliance on capital markets.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Antimony Resources has moved closer to first production in Mexico, but its FY2026 annual report carries a material going-concern warning after a A$7.0 million loss and sharply reduced cash reserves. The company now faces the harder test of turning its Tecomatlán plant and Los Lirios project into cash-generating operations.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Lakes Blue Energy reported a $19.67 million FY26 loss, ended the year with just $433,804 in cash and disclosed a material uncertainty over its ability to continue as a going concern. Its key Wombat-5 well found gas-bearing zones but failed to establish commercial deliverability, leaving the company dependent on further remediation, flow testing and capital.
Victor Sage
Victor Sage
30 Sept 2026
Everlast Minerals has completed its first export shipment from Bangladesh, but the 109-tonne cargo remains a pilot-scale milestone rather than proof of commercial production. The ASX-listed company ended FY26 with $3.32 million in cash, a $3.03 million loss and commissioning still incomplete at its expanded Gaibandha operation.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
Victor Sage
30 Sept 2026

Browse the archive

Full archive